Vir Biotechnology, Inc DEFA14A, filed Apr 7, 2023

Vir Biotechnology, Inc. (VIR)

DEFA14A 2023-04-07

Added on October 20, 2026


☐		Preliminary Proxy Statement

☐		Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

☐		Definitive Proxy Statement

☒		Definitive Additional Materials

☐		Soliciting Material Pursuant to §240.14a-12



☒		No fee required

☐		Fee paid previously with preliminary materials

☐		Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.


Smartphone users		Vote Virtually at the Meeting* May 19, 2023 11:30 AM PT
Point your camera here and
vote without entering a
control number
	Virtually at: www.virtualshareholdermeeting.com/VIR2023


Voting Items		Board Recommends

1.	To elect the following four nominees for director to hold office until the 2026 Annual Meeting of Stockholders

	Nominees:

1a.	Robert More		For

1b.	Janet Napolitano		For

1c.	Vicki Sato, Ph.D.		For

1d.	Elliott Sigal, M.D., Ph.D.		For

2.	To approve, on an advisory basis, the compensation of the Company’s named executive officers.		For

3.	To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.		For

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.


*Please check the meeting materials for any special requirements for meeting attendance.
		V1.1